B.N.Rathi Securities Ltd.

Company Profile

Smart Quotes

TORRENT PHARMACEUTICALS LTD.

NSE : TORNTPHARMBSE : 500420ISIN CODE : INE685A01028Industry : Pharmaceuticals & DrugsHouse : Torrent

BSE2536.6517.25 (+0.68 %)

PREV CLOSE ( ) 2519.40

OPEN PRICE ( ) 2512.35

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1615

TODAY'S LOW / HIGH ( )2508.65 2542.85

52 WK LOW / HIGH ( )1564 2745.55

NSE2537.6017.75 (+0.7 %)

PREV CLOSE( ) 2519.85

OPEN PRICE ( ) 2519.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 2537.60 (60)

VOLUME 119210

TODAY'S LOW / HIGH( ) 2505.30 2546.00

52 WK LOW / HIGH ( )1564.55 2744

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-07 1972

Management Info

Samir Mehta - Chairman - Managing Director

Registered Office

Address Torrent House,Off Ashram Road,,
Ahmedabad,
Gujarat-380009

Phone 079-26599000

Email investorservices@torrentpharma.com

Website www.torrentpharma.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

06Mar USFDA issues EIR to Torrent Pharmaceut
The United States Food and Drug Administration (USFDA) has successfully..

05Feb Torrent Pharmaceuticals hits 52-week h
Torrent Pharmaceuticals is currently trading at Rs. 2679.90, up by 155.2..

03Feb Torrent Pharmaceuticals reports 52% ri
Torrent Pharmaceuticals has reported results for third quarter ended Dec..

02Feb Torrent Pharmaceuticals informs about
Torrent Pharmaceuticals has informed that the Presentation on unaudited..

12Jan Torrent Pharmaceuticals informs about
Torrent Pharmaceuticals has informed that a meeting of the Board of Dire..

Financials

in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	2970	10520
Gross Profit	4300	15770
Operating Profit	6900	25470
Net Sales	21230	76950

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 7519.90 (5.84%)	M.Cap ( in Cr)9647.95
NGL Fine-Chem (BSE) 2264.35 (5.97%)	M.Cap ( in Cr)1398.92
Astrazeneca Pharma I (BSE) 5288.60 (1.85%)	M.Cap ( in Cr)13221.50
Divi's Lab (BSE) 3764.65 (1.32%)	M.Cap ( in Cr)99939.63
Dr. Reddy's Lab (BSE) 6052.00 (0.70%)	M.Cap ( in Cr)100958.41

Shareholding Pattern

	PROMOTERS	71.25%
	NON-INSTITUTION	7.45%
	MUTUAL FUNDS/UTI	4.48%
	FI/BANKS/INSURANCE	1.96%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Aditya Birla SL Pharma & Healthcare Fund-Reg(G)	7.24
LIC MF Healthcare Fund-Reg(G)	5.23
HDFC Pharma and Healthcare Fund-Reg(G)	4.19
Mirae Asset Healthcare Fund-Reg(G)	3.83
Nippon India Nifty Pharma ETF	3.64
ICICI Pru Nifty Pharma Index Fund-Reg(G)	3.64
PGIM India Arbitrage Fund-Reg(G)	3.39

Investor Alert

1) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. 2) For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors. 3) For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors. 4) No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. 5) Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. 6) This is to inform that we B N Rathi securities Ltd not required to have a Business Continuity/DR plan under the existing regulatory provisions.

ATTENTION INVESTORS | KYC | IPO

Prevent Unauthorised transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/DP. Receive information of your transactions directly from Exchanges/Depositories on your mobile/email at the end of the day. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account......Issued in the interest of investors. SEBI Circular - Investor Grievance Redress Mechanism - New Policy Measures. Kindly refer at Policies.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account

REGISTRATION NOS: SEBI Registration No: INZ000160834 (BSE-3233 | NSE-07141| MCX-56475) CDSL : SEBI Regn No. IN-DP-612-2021. AMFI-Registered Mutual Fund Distributor: B.N.Rathi Securities Ltd - ARN-77516: (B.N.Rathi is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.) CIN: L65993TG1985PLC005838

GRIEVANCE CONTACT Investor Grievance Contact: investorgrievances@bnrsecurities.com | DP Investor Grievance: investorgrievances@bnrsecurities.com Investor Protection and Arbitration Exchange Circulars and Rules - NSE,BSE and MCX.

In case of member having a website, member has created awareness amongst clients / investors with regard to procedure of pledge/ re-pledge of securities and displayed the guidelines on the homepage of their respective websites at a prominent place as required in Exchange circular ref no. NSE/INSP/45565 dated Sep 02,2020 Trading members had displayed the set of standard documents/policies on their own website for information.

SEBI SCORES LETTER OF AUTHORITY BROKERS NORMS RMS POLICY PMLA-POLICY SURVEILLANCE POLICY KYC MANDATORY - 6 ATTRIBUTES EVoting CDSL EVoting NSDL

DISCLAIMER INACTIVE CLIENT POLICY PRIVACY POLICY TERMS & CONDITIONS COMPANY POLICIES INVESTOR GRIEVANCE REDRESSAL POLICY INVESTOR CHARTER INVESTOR CHARTER - DP INVESTOR CHARTER - RESEARCH ANALYST INVESTOR CHARTER IGC MIS ADVISORY FOR INVESTORS BNRSL-DISCLAIMERS RESEARCH REPORTS